Archive for the ‘Commercialization’ Category
Why the pen is sometimes mightier than the pipette – Part 2
. Last week I posted a summary of the first half of a full day Communications for Scientists workshop organized by the Stem Cell Network. This post picks up where I left off, with a description of a “Dragon’s Den” style pitch session intended to introduce trainees to necessary communications skills within a commercialization context. The…Read more
How many facilities? Centralized vs. decentralized manufacture
When it comes to the cell therapy commercialization crunch there are some fundamental questions that need to be answered. Is your product going to be frozen or fresh? How will the product be administered? What is your dosing strategy? And the one that I’m going to focus on in this blog: Will your manufacturing strategy…Read more
Cell therapy industry 2027: Lone ranger or team player?
claimtoken-510012802486f This post was initially intended to be a short vignette (not so short, as it turns out) exploring whether or not the Cell Therapy Industry 2027 required a vade mecum – a single point of reference for all practitioners. It was prompted by a conversation with London’s chirpiest cabbie who offered an extraordinarily pithy…Read more
Creating an ecosystem for Canadian RM commercialization
James Till and Ernest McCulloch identified stem cells 50 years ago in Toronto, and their legacy is a vibrant community of scientists who are leaders in this field of research. But what does that mean in terms of producing products and therapies to heal and cure patients? While Canada is an acknowledged leader in the…Read more
Cell therapy industry 2027: Business models, best practices and big data
Recently, in the twilight on a balmy summer’s evening in DC, an irrationally passionate cell therapy war room convened over meze, ouzo and retsina. And considered the meaty question posed by Lonza’s Jon Rowley: “Where do you think you and the cell therapy industry will be in fifteen years?” I anticipate there will be three…Read more
All business (no hype) in commercializing regenerative medicine
My grandmother, at 97, is excited about stem cell research because she sees the possibilities. Regenerative medicine IS an exciting field. It’s on the cutting edge of science and fans and critics alike debate its merits regularly in the press and in blogs. Every day, we read stories with headlines that proclaim stem cells will…Read more
The Commercialization of Regenerative Medicine: Turning Corners
The health-care landscape is changing: the previous model of the blockbuster pharmaceutical is being challenged by new therapies that have the potential to offer more effective treatments. In this new contribution to Signals Blog, I describe the present landscape for regenerative medicine commercialization. The current health-care system is being pushed to the brink. Driven by…Read more
BioTime: A new Geron, without a decade of baggage
Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some detail last month, and the transaction itself follows a Letter of Intent announced last November, which valued it at approximately $71 million. The transaction leaves Geron to…Read more